Sarepta Therapeutics, Inc. SRPT
Set alert
At close · Oct 30
After hours · Oct 30, 7:52 PM ET
- YTD
- -13.48%
- 1 year
- -19.91%
- Open
- 19.04
- Prev close
- 19.23
- Mkt cap
- 1.97B
- Vol
- 1.32M
- Avg vol
- 2.94M
- EPS
- -1.57
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 18.41
- High
- 19.50
- Forward P/E
- 7.53
- Beta
- 0.38
- Short ratio
- 7.84
- Inst. own
- 103.39%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 19.25
- 200-d avg
- 18.74
- 1y target
- 21.64
5D chart
Signals (121)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 2:30 PM | 1 day ago |
| SMA: Bullish | Oct 30, 2:25 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 1:55 PM | 1 day ago |
| RSI: Oversold | Oct 30, 1:35 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 1:15 PM | 1 day ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 11:55 AM | 2 days ago |
| RSI: Oversold | Oct 30, 11:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:20 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:55 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:40 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:40 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:40 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:35 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:50 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:25 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:20 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:15 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 2 days ago |
| RSI: Oversold | Oct 29, 2:30 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 29, 1:30 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 1:25 PM | 2 days ago |
| SMA: Bullish | Oct 29, 1:15 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:05 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:35 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 2:10 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 2:05 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 2:05 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:45 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 28, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 28, 1:15 PM | 3 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:00 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:35 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 10:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 9:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:30 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 4 days ago |
| RSI: Overbought | Oct 27, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:35 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:35 PM | 4 days ago |
| RSI: Overbought | Oct 27, 2:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:00 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 4 days ago |
| SMA: Bearish | Oct 27, 1:15 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:30 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:30 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:20 PM | 5 days ago |
| RSI: Overbought | Oct 27, 12:10 PM | 5 days ago |
| RSI: Overbought | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:30 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:00 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 26, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:40 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:35 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:00 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:55 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:15 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:05 PM | 5 days ago |
| MACD: Sell Signal | Oct 26, 1:05 PM | 5 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:10 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:25 AM | 6 days ago |
News
3 days ago zacks.com
Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 days ago businesswire.com
Sarepta Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the…
1 week ago businesswire.com
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the…
1 week ago defenseworld.net
Analyzing Protagonist Therapeutics (NASDAQ:PTGX) and Sarepta Therapeutics (NASDAQ:SRPT)
Protagonist Therapeutics (NASDAQ: PTGX - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior investment? We will…
2 weeks ago businesswire.com
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the 22nd Annual…
-
3 weeks ago benzinga.com
RBC Capital Maintains Sector Perform on Sarepta Therapeutics, Lowers Price Target to $17
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sector Perform and lowers the price target from $19 to $17.
3 weeks ago benzinga.com
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner'
On CNBC's “Mad Money Lightning Round,” Jim Cramer said Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a “very controversial” stock.
3 weeks ago benzinga.com
Jim Cramer: This Tech Stock Is 'Very Good,' Avery Dennison Is A ‘Winner’
Cramer called Sarepta controversial, praised Avery Dennison and Ciena, favored ING and Santander, and declined to endorse FirstCash.
3 weeks ago businesswire.com
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has…
3 weeks ago defenseworld.net
Sarepta Therapeutics (NASDAQ:SRPT) Given Sell Rating at HC Wainwright
Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report)'s stock had its "sell" rating reissued by HC Wainwright in a research report issued on Monday, MarketBeat.com reports. They currently have a…
-
3 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
1 month ago businesswire.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously…
-
1 month ago benzinga.com
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
-
1 month ago benzinga.com
Sarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne Muscular Dystrophy
Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2…
1 month ago businesswire.com
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the…
1 month ago businesswire.com
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for…
1 month ago businesswire.com
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study…
-
1 month ago benzinga.com
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement") with Sarepta
1 month ago defenseworld.net
Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT
Squarepoint Ops LLC cut its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 36.5% in the second quarter, according to the company in its most recent Form 13F filing with the…
1 month ago marketbeat.com
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
Sarepta Therapeutics NASDAQ: SRPT outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic…
1 month ago seekingalpha.com
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago benzinga.com
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
1 month ago benzinga.com
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Sarepta Therapeutics Inc. (NASDAQ:SRPT) stock is trading lower on Tuesday in reaction to Novartis AG's (NYSE:NVS) data from the global Phase 3 HARBOR study of del-desiran for myotonic dystrophy type…
1 month ago benzinga.com
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
1 month ago reuters.com
Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers
Shares of Dyne Therapeutics and Sarepta slumped on Tuesday after Novartis' treatment for a muscle-wasting disorder failed in a trial, fueling investor concerns about the prospects of similar…
1 month ago gurufocus.com
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Sc
1 month ago businesswire.com
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne…
1 month ago benzinga.com
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
1 month ago benzinga.com
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
1 month ago defenseworld.net
Comparing Alector (NASDAQ:ALEC) and Sarepta Therapeutics (NASDAQ:SRPT)
Alector (NASDAQ: ALEC - Get Free Report) and Sarepta Therapeutics (NASDAQ: SRPT - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two…
2 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
-
2 months ago benzinga.com
Sarepta Therapeutics Q2 Adj. EPS $0.64 Beats $0.26 Estimate, Sales $401.300M Beat $364.343M Estimate
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.26 by 146.15 percent. This is a 68.32 percent decrease over earnings…
-
3 months ago benzinga.com
Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug Ingram
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective…
-
3 months ago benzinga.com
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
-
3 months ago benzinga.com
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target
Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.
4 months ago benzinga.com
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy Drugs
FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a decision expected by February 2027.
-
4 months ago benzinga.com
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027
– Accepted for review with target action date of February 28, 2027Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S.…
4 months ago benzinga.com
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market Today
U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps leading the tape, as investors held their fire ahead of Kevin Warsh‘s first interest-rate decision as…
-
6 months ago benzinga.com
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
6 months ago benzinga.com
9 Health Care Stocks With Whale Alerts In Today's Session
9 Health Care Stocks With Whale Alerts In Today's Session
7 months ago benzinga.com
Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?
U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100, heavily weighted toward tech stocks, officially entered correction territory.
7 months ago benzinga.com
Crude Oil Moves Lower; Cintas Raises FY2026 Forecast
The Dow Jones index gained over 300 points, with the S&P 500 and NASDAQ also rising. Cintas Corp posted strong earnings and raised its forecast, while Sarepta Therapeutics and Braze Inc saw…
7 months ago benzinga.com
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings
US stocks rise with the Dow gaining over 300 points. Chewy shares jump 14%. Sarepta Therapeutics surges 29%. Oil down 2.1%, gold up 3.2%.
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
7 months ago benzinga.com
Stocks Rise, Oil Falls On Iran Ceasefire Hopes, ARM Surges 15% : What's Moving Markets Wednesday?
U.S. stocks advanced Wednesday as oil prices fell on Iran diplomacy reports. Arm jumped 15%, while Treasury yields declined.
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
9 months ago benzinga.com
Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday?
Natural gas jumps over 30% on winter storm disruptions, silver posts its biggest daily surge since 2008, and stocks grind higher.
9 months ago benzinga.com
Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday
Sarepta Therapeutics, Lands' End, USA Rare Earth, CoreWeave And Other Big Stocks Moving Higher On Monday
9 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today's Session
10 Health Care Stocks Whale Activity In Today's Session